Investor Fact Sheet

Company Name: Amplia Therapeutics Limited (ACN 165 160 841)

Business Description:

Amplia Therapeutics Limited (ASX: ATX) is an Australian pharmaceutical company that is advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic cancer. FAK also plays a significant role in a number of fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF).


Shares on Issue: 271,609,233 Fully Paid Ordinary Shares
Options on Issue:

16,771,000 Unlisted Options (at varying exercise prices and expiry dates)

 


Market Listings:

Australian Securities Exchange (ASX Code: ATX)


Directors:

Dr Warwick Tong, Chairman, Non-Executive Director
Dr Chris Burns, CEO and Managing Director
Dr Robert Peach, Independent Non-Executive Director
Ms Jane Bell AM, Independent Non-Executive Director


Management:

Dr Chris Burns, CEO and Managing Director
Mr Tim Luscombe, Chief Financial Officer
Dr Rhiannon Jones, Chief Operating Officer
Mr Andrew Cooke, Company Secretary


Registered Office:

Level 17
350 Queen Street
Melbourne VIC 3000
Australia


Auditors:

Grant Thornton Audit Pty
GPO Box 4736
Melbourne 3001
Australia